Acadian Asset Management LLC Decreases Stock Holdings in Cellebrite DI Ltd. $CLBT

Key Points

• Acadian Asset Management LLC reduced its stake in Cellebrite DI Ltd. by 17.7%, selling 845,036 shares and holding approximately 3.9 million shares valued at $76.1 million.
• Institutional investors own 45.88% of Cellebrite DI's stock, with significant increases in stakes reported by firms like Invesco Ltd. and Handelsbanken Fonder AB during the first quarter.
• Recent analyst ratings show a positive trend, with a consensus target price of $22.40 and several firms upgrading their ratings to "buy," despite a lowered price target from some analysts.

Acadian Asset Management LLC lowered its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 17.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,918,450 shares of the company's stock after selling 845,036 shares during the quarter. Acadian Asset Management LLC owned about 1.64% of Cellebrite DI worth $76,106,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Voss Capital LP lifted its position in Cellebrite DI by 18.6% during the first quarter. Voss Capital LP now owns 3,843,602 shares of the company's stock valued at $74,681,000 after buying an additional 603,602 shares during the period. Invesco Ltd. lifted its position in Cellebrite DI by 122.1% during the first quarter. Invesco Ltd. now owns 3,296,079 shares of the company's stock valued at $64,043,000 after buying an additional 1,811,757 shares during the period. T. Rowe Price Investment Management Inc. purchased a new position in Cellebrite DI during the first quarter valued at $60,939,000. Two Sigma Advisers LP lifted its position in Cellebrite DI by 35.0% during the fourth quarter. Two Sigma Advisers LP now owns 1,811,100 shares of the company's stock valued at $39,899,000 after buying an additional 470,000 shares during the period. Finally, Handelsbanken Fonder AB lifted its position in Cellebrite DI by 749.9% during the first quarter. Handelsbanken Fonder AB now owns 1,518,700 shares of the company's stock valued at $29,508,000 after buying an additional 1,340,000 shares during the period. Hedge funds and other institutional investors own 45.88% of the company's stock.

Cellebrite DI Trading Down 2.2%

NASDAQ:CLBT traded down $0.38 during mid-day trading on Friday, reaching $16.80. The company's stock had a trading volume of 1,572,538 shares, compared to its average volume of 2,185,428. Cellebrite DI Ltd. has a 12-month low of $13.10 and a 12-month high of $26.30. The firm's fifty day moving average price is $15.18 and its two-hundred day moving average price is $16.97. The stock has a market cap of $4.02 billion, a P/E ratio of -22.11, a PEG ratio of 3.12 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its earnings results on Thursday, August 14th. The company reported $0.12 earnings per share for the quarter, topping analysts' consensus estimates of $0.11 by $0.01. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The business had revenue of $113.28 million during the quarter, compared to analyst estimates of $112.33 million. During the same quarter in the previous year, the firm earned $0.10 EPS. Cellebrite DI's revenue was up 18.4% on a year-over-year basis. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Lake Street Capital reduced their price target on Cellebrite DI from $24.00 to $22.00 and set a "buy" rating for the company in a report on Friday, August 15th. Needham & Company LLC reduced their price target on Cellebrite DI from $24.00 to $18.00 and set a "buy" rating for the company in a report on Thursday, August 14th. Finally, Wall Street Zen upgraded Cellebrite DI from a "hold" rating to a "buy" rating in a report on Saturday, August 16th. Five analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $22.40.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.